查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011573

伴侶動物用藥品市場：2026-2032年全球市場預測（依動物種類、產品類型、劑型、通路及治療領域分類）

Companion Animal Health Market by Animal Type, Product Type, Formulation, Distribution Channel, Therapeutic Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，寵物藥品市場價值將達到 471.3 億美元，到 2026 年將成長至 550.1 億美元，到 2032 年將達到 1,518.2 億美元，複合年成長率為 18.18%。

主要市場統計數據
基準年 2025 471.3億美元
預計年份：2026年 550.1億美元
預測年份 2032 1518.2億美元
複合年成長率 (%) 18.18%

對伴侶動物健康產業前景的展望，涵蓋了不斷成長的需求促進因素、不斷變化的相關人員以及策略重點。

受飼主期望變化、技術進步和護理模式演變的推動，伴侶動物醫療保健產業正經歷快速轉型。寵物飼主越來越將動物視為家庭成員，因此對先進診斷、專業營養管理和創新治療方法的需求日益成長。同時，獸醫診所和銷售合作夥伴也在調整其商業模式，並重組服務和產品交付方式，以適應遠端醫療、居家監控和全通路購買行為。

數位轉型、個人化照護模式和供應鏈韌性如何重塑獸醫學領域的產品路徑和競爭優勢。

伴侶動物醫療保健生態系統正受到多重因素的共同影響而重塑，這些因素正在改變產品開發、臨床實踐和商業性合作模式。首先，數位化和連線健診工具正從先導計畫發展成為醫療服務的核心要素，從而能夠早期發現慢性疾病，並促進獸醫與飼主之間更頻繁的遠端互動。這些工具正在產生新的資料流，為以結果主導的價值提案和產品差異化提供支援。

本研究評估了累積關稅壓力將如何影響伴侶動物治療、診斷和營養產品的整個供應鏈的採購、定價和准入。

主要貿易夥伴預期採取的關稅措施可能會對進口原料、成品或專用設備的伴侶動物保健公司產生累積影響。實際上，關稅增加可能會提高製造商和經銷商的接收成本，除非透過價格調整、採購管道變更或提高營運效率來抵消，否則可能會擠壓利潤空間。對於依賴跨境生產注射劑、診斷組件或藥物活性成分的企業而言，關稅風險可能會增加採購風險，並促使其將生產外包或實現供應商多元化。

詳細的細分分析將動物種類、產品類型、配方選擇和分銷管道的趨勢與臨床應用和商業性機會聯繫起來。

為了深入了解市場動態，必須從多個細分觀點來掌握需求和採納模式，從而指導產品設計和商業性執行。就動物種類而言，犬類仍然是預防醫學和慢性病護理領域創新的主要目標，而貓則推動了隱藏式家庭護理和專業營養管理的普及。同時，馬匹市場優先考慮具有獨特臨床路徑的性能提升、繁殖和疼痛管理解決方案。就產品類型而言，診斷技術的進步，從影像學和體外診斷到連續監測，使得早期發現和更精準的治療方法方案成為可能；而營養創新則側重於針對生命週期需求和合併症管理的專用寵物食品配方和補充劑。藥品涵蓋範圍廣泛，從抗發炎藥物和抗生素到內分泌療法、鎮痛藥和驅蟲藥，每種藥物都有其獨特的監管規定、定價和合理使用注意事項。

影響美洲、歐洲、中東和非洲以及亞太市場差異化商業化策略的區域趨勢。

臨床實務、法規環境和消費者偏好的區域差異造就了鮮明的區域趨勢，進而影響著參與企業和現有企業的策略重點。在美洲，成熟的獸醫網路、較高的寵物擁有率以及消費者在預防保健和先進治療方面的強烈消費意願，使得市場准入和臨床證據成為企業脫穎而出的關鍵手段。同時，供應鏈因素和報銷機制也影響製造商在國家和地方市場中如何優先分配分銷和促銷投資。

策略重點和競爭對手策略，幫助企業在動物保健領域取得成功，結合臨床可靠性、供應確定性和先進的分銷管道。

在伴侶動物健康領域，競爭優勢越來越取決於能否將科學可靠性與可擴展的商業性可行性結合。主要企業正優先建立整合診斷、治療和營養解決方案的綜合產品組合，並以療效數據和臨床醫生培訓計畫為支持。策略聯盟和選擇性收購是拓展能力、獲取專有技術以及加速進入相鄰治療和分銷領域的常用方法。

為高階主管提供可操作的策略措施，以增強證據產生、供應鏈韌性和跨通路的商業性差異化。

產業領導者應制定多管齊下的行動計劃，旨在確保臨床信心、最佳化供應鏈並加速商業性化應用。首先，應優先建立強力的臨床和真實世界證據，以證明產品在改善患者療效和提升飼主滿意度方面取得了可衡量的進步。這將有助於加強與獸醫界意見領袖的關係，並鞏固產品的高階定位。其次，應重新設計籌資策略，透過供應商多元化、盡可能本地化生產以及柔軟性的庫存管理來降低關稅和物流風險，從而即使在供應中斷的情況下也能維持服務水準。

結合從業者訪談、監管分析和情境規劃的穩健混合方法研究途徑，檢驗了商業性和臨床發現。

本分析所依據的研究採用了一種混合方法，結合了定性和定量證據的收集、嚴謹的二手資料研究以及專家檢驗。關鍵資料來源包括對臨床獸醫、分銷主管和產品開發經理的結構化訪談，從而深入觀點臨床工作流程、推廣障礙和分銷管道的經濟效益。二手資料研究則納入了監管指南、臨床文獻和行業趨勢分析，以更好地理解訪談結果並識別系統性因素。

將臨床創新、營運韌性和實證商業化聯繫起來，作為動物醫學長期成功的支柱，並得出相關結論。

總而言之，伴侶動物醫療保健正步入策略整合與創新時代，臨床證據、供應鏈靈活性和完善的分銷管道將決定最終的贏家。診斷技術和數位健康能力的進步正在改變醫療服務的節奏，使早期療育成為可能，並為那些能夠展現顯著療效的產品和服務創造了機會。兼顧配方便捷性和治療效果的營養品和藥品組合將越來越受到飼主的青睞，並獲得臨床醫師的支持。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 伴侶動物用藥品市場：依動物類型分類

  • 貓
  • 狗
  • 馬

第9章 伴侶動物用藥品市場：依產品類型分類

  • 診斷
    • 診斷影像
    • 體外診斷試劑
    • 監控設備
  • 營養
    • 寵物專用食品
    • 補充
  • 製藥
    • 抗發炎藥
    • 抗生素
    • 內分泌治療
    • 疼痛管理
    • 殺蟲劑
  • 疫苗

第10章 伴侶動物用藥品劑型分類）

  • 注射藥物
  • 口服
  • 外用

第11章 伴侶動物用藥品市場：依通路分類

  • 線上零售
  • 寵物專賣店
  • 藥局
  • 動物醫院

第12章 伴侶動物用藥品市場：依治療領域分類

  • 循環系統
  • 牙科
  • 皮膚科
  • 內分泌
  • 整形外科
  • 寄生蟲學

第13章 伴侶動物用藥品市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 伴侶動物用藥品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 伴侶動物用藥品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國伴侶動物用藥品市場

第17章：中國伴侶動物用藥品市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Blue Buffalo Co., Ltd.
  • Boehringer Ingelheim Animal Health
  • Ceva Sante Animale
  • Covetrus
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Heska Corporation
  • Hill's Pet Nutrition, Inc.
  • IDEXX Laboratories, Inc.
  • Kindred Biosciences, Inc.
  • Mars Petcare Inc.
  • Merck Animal Health
  • Nestle Purina PetCare
  • Patterson Companies, Inc.
  • Royal Canin SAS
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-4330CC794B35

The Companion Animal Health Market was valued at USD 47.13 billion in 2025 and is projected to grow to USD 55.01 billion in 2026, with a CAGR of 18.18%, reaching USD 151.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.13 billion
Estimated Year [2026] USD 55.01 billion
Forecast Year [2032] USD 151.82 billion
CAGR (%) 18.18%

A compelling orientation to the companion animal health sector that frames rising demand drivers, stakeholder shifts, and priority areas for strategic action

The companion animal health landscape is undergoing an era of accelerated transformation driven by shifting owner expectations, technological advances, and evolving care models. Pet guardians increasingly view animals as integral family members, which has elevated demand for advanced diagnostics, specialized nutrition, and novel therapeutics. Concurrently, veterinary practices and channel partners are adapting operating models to accommodate telehealth, at-home monitoring, and omnichannel purchasing behaviors, reshaping how services and products are delivered.

Against this backdrop, commercial stakeholders must integrate clinical evidence, consumer insights, and supply chain resilience into strategic decision-making. Investment priorities are moving toward solutions that enable remote monitoring, improve diagnostic throughput, and deliver measurable clinical outcomes that resonate with both clinicians and owners. Moreover, regulatory scrutiny and antimicrobial stewardship initiatives are influencing formulary decisions and product development pathways. In combination, these dynamics create both challenges and opportunities for innovators, manufacturers, and distributors seeking to differentiate offerings and scale adoption across veterinary networks and retail channels.

Looking ahead, leaders who align scientific rigor with pragmatic commercialization strategies, and who anticipate shifting distribution and pricing pressures, will be best positioned to capture long-term value in this rapidly maturing sector.

How digital transformation, personalized care models, and supply chain resilience are reshaping product pathways and competitive advantage in animal health

The companion animal health ecosystem is being redefined by several convergent shifts that are transforming product development, clinical practice, and commercial engagement. First, digital and connected health tools are moving from pilot projects to core components of care delivery, enabling earlier detection of chronic conditions and more frequent remote interactions between veterinarians and owners. These tools are catalyzing new data streams that support outcome-driven value propositions and product differentiation.

Second, there is a pronounced move toward personalized and preventative approaches, with nutritional strategy and targeted therapeutics increasingly tailored to life stage, breed predispositions, and comorbidities. This trend is reinforced by growing consumer willingness to invest in premium care and by clinicians seeking evidence-based interventions that extend quality of life. Third, supply chain agility and sourcing transparency have become strategic imperatives as manufacturers and distributors respond to fluctuating input availability and evolving regulatory requirements. Together, these shifts elevate the importance of cross-functional collaboration among R&D, regulatory, and commercial teams.

Finally, the competitive landscape is intensifying as new entrants and incumbent manufacturers expand portfolios across diagnostics, nutrition, pharmaceuticals, and vaccines. The cumulative effect of these transformative shifts is a market where clinical credibility, digital integration, and channel sophistication determine who advances from niche adoption to mainstream acceptance.

Assessing how cumulative tariff pressures influence procurement, pricing, and access across companion animal therapeutics, diagnostics, and nutrition supply chains

Projected tariff actions originating from major trading partners can exert a cumulative influence on companion animal health companies that import raw materials, finished goods, or specialized equipment. In practical terms, higher duties increase landed costs for manufacturers and distributors, which can compress margins unless offset through pricing adjustments, re-sourcing, or operational efficiencies. For organizations that rely on cross-border production of injectables, diagnostics components, or pharmaceutical active ingredients, tariff exposure heightens procurement risk and may incentivize nearshoring or supplier diversification.

Beyond direct cost effects, tariff-induced shifts can create secondary impacts across supply chains and consumer behavior. For example, increased import costs may delay product launches or reduce promotional intensity as firms prioritize inventory allocation and working capital preservation. In turn, veterinarians and pet owners may experience constrained access to certain imported diagnostics or specialized nutritional formulations, prompting substitution toward locally produced alternatives or generics. Regulatory compliance and customs administration requirements can also extend lead times, making demand planning more complex and increasing the value of flexible inventory strategies.

To mitigate cumulative tariff impacts, stakeholders are advised to evaluate scenario-based sourcing strategies, renegotiate commercial terms where feasible, and accelerate product localization efforts. Ultimately, the resilience of manufacturing footprints and the agility of distribution networks will determine how effectively companies absorb tariff pressures while maintaining service levels for clinics and consumers.

Deep segmentation intelligence linking animal type, product architecture, formulation choices, and channel dynamics to clinical adoption and commercial opportunity

A granular view of market dynamics requires understanding demand and adoption patterns across multiple segmentation lenses that guide product design and commercial execution. When viewed through animal type, dogs remain a primary focus for preventive and chronic care innovations, while cats drive adoption in discreet, at-home treatments and specialized nutrition; equine markets prioritize performance, reproduction, and pain management solutions with distinct clinical pathways. Considering product type, diagnostic advances spanning imaging, in-vitro diagnostics, and continuous monitoring are enabling earlier detection and more precise treatment selection, whereas nutrition innovation emphasizes specialized pet food formulations and supplements that target lifecycle needs and comorbidity management. Pharmaceuticals encompass a range of modalities from anti-inflammatories and antibiotics to endocrine therapies, analgesics, and parasiticides, each with unique regulatory, pricing, and stewardship considerations.

Formulation choices-injectable, oral, and topical-continually influence prescribing behavior and owner adherence, with injectables favored for clinic-administered interventions, oral formulations supporting at-home chronic disease management, and topicals offering convenience for dermatological and parasitology indications. Distribution channel dynamics further shape access and purchasing patterns; online retail platforms are expanding reach and convenience, pet specialty stores maintain brand discovery roles, pharmacies offer trusted dispensing, and veterinary clinics remain central for professional guidance and point-of-care product use. Therapeutic area focus on cardiovascular, dental, dermatology, endocrine, orthopedic, and parasitology conditions highlights where clinical demand and innovation pipelines intersect, creating differentiated opportunities for targeted clinical evidence generation and tailored commercial strategies.

Taken together, these segmentation perspectives underscore the importance of integrated product planning that aligns formulation, channel strategy, and therapeutic positioning to clinical workflows and owner behaviors in order to accelerate adoption and sustain value.

Regional dynamics that dictate differentiated commercialization playbooks across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Geographic variation in clinical practice, regulatory environments, and consumer preferences creates distinct regional dynamics that shape strategic priorities for market entrants and incumbents alike. In the Americas, established veterinary networks, high pet ownership rates, and strong consumer propensity to spend on preventative and advanced care make market access and clinical evidence the primary levers for differentiation. Meanwhile, supply chain considerations and reimbursement structures influence how manufacturers prioritize distribution and promotional investments across national and subnational markets.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with diverse market maturity levels, creating opportunities for regionally tailored product registrations and differentiated channel strategies. Local clinical guidelines and antimicrobial stewardship programs in parts of this region can affect pharmaceutical utilization patterns, prompting manufacturers to emphasize stewardship-aligned messaging and diagnostic-enabled prescribing. Across the Asia-Pacific region, rapid pet ownership growth, expanding urban veterinary infrastructures, and rising disposable incomes are accelerating demand for premium nutrition, modern diagnostics, and accessible therapeutic options, while market entry strategies must account for varied regulatory landscapes and local manufacturing incentives.

Collectively, these regional insights point to the need for flexible commercialization frameworks that balance global clinical evidence generation with localized regulatory strategies, channel partnerships, and marketing approaches adapted to differing consumer behaviors and healthcare delivery models.

Strategic corporate priorities and competitive moves that combine clinical credibility, supply reliability, and channel sophistication to win in animal health

Competitive positioning in companion animal health is increasingly determined by the ability to combine scientific credibility with scalable commercial execution. Leading companies are prioritizing integrated portfolios that blend diagnostics, therapeutics, and nutritional solutions, supported by outcome data and clinician education programs. Strategic alliances and selective acquisitions are common approaches to broaden capability sets, access proprietary technologies, and accelerate entry into adjacent therapeutic or distribution segments.

Operational excellence in manufacturing and regulatory affairs remains critical, particularly for injectable biologics and advanced diagnostics that require stringent quality systems. Organizations that invest in supply chain visibility and digital forecasting tools gain advantages in inventory optimization and service continuity. On the commercial front, digital marketing, omnichannel sales enablement, and enhanced field force training support more effective engagement with veterinary practices and pet owners. Moreover, a growing emphasis on post-market evidence and real-world data collection strengthens clinical value propositions and supports payer or institutional procurement discussions.

In this competitive environment, nimble mid-sized firms can outmaneuver larger incumbents by focusing on niche therapeutic areas or by offering differentiated, clinician-facing diagnostic platforms. Conversely, large integrated players leverage scale to deliver global supply continuity and broad distribution, making partnerships with regional specialists an effective route to localized growth.

Actionable strategic moves for executives to strengthen evidence generation, supply resilience, and commercial differentiation across channels

Industry leaders should pursue a multi-pronged action agenda designed to secure clinical trust, optimize supply chains, and accelerate commercial adoption. First, prioritize the generation of robust clinical and real-world evidence that demonstrates measurable improvements in patient outcomes and owner satisfaction; this will strengthen relationships with veterinary opinion leaders and support premium positioning. Next, redesign sourcing strategies to reduce tariff and logistical exposure through supplier diversification, localized production where feasible, and inventory flexibility that preserves service levels during disruptions.

Simultaneously, invest in digital infrastructure that supports remote monitoring, telehealth integration, and omnichannel commerce, thereby capturing new engagement points and improving adherence. Commercial teams should develop channel-specific value propositions tailored to online retailers, specialty stores, pharmacies, and clinic partners, ensuring consistent messaging and streamlined fulfillment options. Additionally, embed antimicrobial stewardship and regulatory compliance into product strategies to mitigate reputational and regulatory risk while demonstrating clinical responsibility. Finally, explore partnerships and targeted M&A to acquire niche technologies or distribution reach, accelerating time to market for high-value innovations.

By implementing these recommendations, organizations can build resilient, evidence-driven portfolios that address clinical needs and changing owner expectations while safeguarding margin and access in an increasingly complex global environment.

Robust mixed-method research approach combining practitioner interviews, regulatory analysis, and scenario planning to validate commercial and clinical insights

The research underpinning this analysis draws on a blended methodology combining qualitative and quantitative evidence collection, rigorous secondary research, and expert validation. Primary inputs included structured interviews with practicing veterinarians, distribution executives, and product development leaders, providing perspective on clinical workflows, adoption barriers, and channel economics. Secondary research encompassed regulatory guidance, clinical literature, and industry trend analyses to contextualize interview findings and identify systemic drivers.

Analytical methods included cross-segmentation synthesis to evaluate how animal type, product typology, formulation, distribution channel, and therapeutic focus interact to influence adoption and commercial outcomes. Scenario planning and sensitivity analysis were applied to assess potential impacts of external shocks such as tariff adjustments and supply chain disruptions. All findings were triangulated with expert review panels to ensure interpretive rigor and practical relevance. Limitations of the study are acknowledged where data variability or rapidly evolving regulatory conditions may affect near-term applicability, and recommendations are provided with pathways for targeted validation through additional primary research or pilot programs.

This multi-method approach ensures the insights are grounded in clinical reality, commercially actionable, and adaptable to evolving market conditions.

Concluding synthesis that links clinical innovation, operational resilience, and evidence-driven commercialization as the pillars of long-term success in animal health

In summary, companion animal health is entering a period of strategic consolidation and innovation where clinical evidence, supply chain agility, and channel sophistication will determine winners. Diagnostic advancements and digital health capabilities are changing the tempo of care, enabling earlier intervention and creating opportunities for products and services that demonstrate clear outcome benefits. Nutrition and pharmaceutical portfolios that align formulation convenience with therapeutic effectiveness will capture increasing owner investment and clinician preference.

Tariff-related pressures and regional regulatory variation require proactive sourcing and market entry strategies to preserve access and margin. Companies that integrate robust evidence generation with adaptive manufacturing footprints and differentiated commercial models will be better positioned to navigate volatility and secure sustainable growth. Ultimately, the path to long-term success relies on translating clinical innovation into scalable, practitioner-validated solutions that meet evolving owner expectations while upholding standards of stewardship and safety.

Stakeholders who act now to align R&D priorities, operational capabilities, and market access strategies will create durable competitive advantage in a rapidly maturing market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Animal Health Market, by Animal Type

  • 8.1. Cat
  • 8.2. Dog
  • 8.3. Horse

9. Companion Animal Health Market, by Product Type

  • 9.1. Diagnostics
    • 9.1.1. Imaging
    • 9.1.2. In Vitro Diagnostics
    • 9.1.3. Monitoring Devices
  • 9.2. Nutrition
    • 9.2.1. Specialized Pet Food
    • 9.2.2. Supplements
  • 9.3. Pharmaceuticals
    • 9.3.1. Anti-Inflammatories
    • 9.3.2. Antibiotics
    • 9.3.3. Endocrine Treatments
    • 9.3.4. Pain Management
    • 9.3.5. Parasiticides
  • 9.4. Vaccines

10. Companion Animal Health Market, by Formulation

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical

11. Companion Animal Health Market, by Distribution Channel

  • 11.1. Online Retail
  • 11.2. Pet Specialty Stores
  • 11.3. Pharmacies
  • 11.4. Veterinary Clinics

12. Companion Animal Health Market, by Therapeutic Area

  • 12.1. Cardiovascular
  • 12.2. Dental
  • 12.3. Dermatology
  • 12.4. Endocrine
  • 12.5. Orthopedic
  • 12.6. Parasitology

13. Companion Animal Health Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Companion Animal Health Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Companion Animal Health Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Companion Animal Health Market

17. China Companion Animal Health Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Blue Buffalo Co., Ltd.
  • 18.6. Boehringer Ingelheim Animal Health
  • 18.7. Ceva Sante Animale
  • 18.8. Covetrus
  • 18.9. Dechra Pharmaceuticals PLC
  • 18.10. Elanco Animal Health Incorporated
  • 18.11. Heska Corporation
  • 18.12. Hill's Pet Nutrition, Inc.
  • 18.13. IDEXX Laboratories, Inc.
  • 18.14. Kindred Biosciences, Inc.
  • 18.15. Mars Petcare Inc.
  • 18.16. Merck Animal Health
  • 18.17. Nestle Purina PetCare
  • 18.18. Patterson Companies, Inc.
  • 18.19. Royal Canin SAS
  • 18.20. Vetoquinol S.A.
  • 18.21. Virbac SA
  • 18.22. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION ANIMAL HEALTH MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPANION ANIMAL HEALTH MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DOG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY HORSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SPECIALIZED PET FOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PET SPECIALTY STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ENDOCRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY PARASITOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 190. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. GCC COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 210. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. G7 COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 219. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL COMPANION ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA COMPANION ANIMAL HEALTH MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)